Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mavacoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 14/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | PDPK1 | O15530 | 7/20 | 0.80 |
| ▸ | PTGES | O14684 | 1/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.80 |
| ▸ | CA12 | O43570 | 1/20 | 0.80 |
| ▸ | PDE5A | O76074 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.80 |
| ▸ | CA1 | P00915 | 1/20 | 0.80 |
| ▸ | CA2 | P00918 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CA3 | P07451 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246379 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL6342351 | 0.95 | PTGS2 (0.90) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL152885 | 0.90 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL6344437 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL6013968 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL3096416 | 0.90 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL6013946 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL3900112 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| SCHEMBL5923919 | 0.89 | PDPK1 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES | |
| Celecoxib SCHEMBL3669597 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9PDPK1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 986 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| EP-3917908-B1 | A CONTINUOUS FLOW MICRO-TOTAL PROCESS SYSTEM FOR PREPARATION OF CELECOXIB AND ANALOGS THEREOF | COUNCIL SCIENT IND RES (IN) | 2024-08-14 | — | — | EP | claimed |
| CN-115754084-B | Analysis method of mycophenolate mofetil | 天和药业有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-4389147-A2 | THERAPEUTIC FORMULATIONS AND USES THEREOF | Dechra Veterinary Products, LLC (US) | 2024-06-26 | — | — | EP | claimed |
| EP-3664800-B1 | THERAPEUTIC FORMULATIONS COMPRISING COX-2 INHIBITOR AND USES THEREOF | DECHRA VETERINARY PRODUCTS LLC (US) | 2024-05-08 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ASAH2, ASAH1, GBA2 | PTGS2 535/4885PTGS1 1433/4885CYP2C9 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.